Sysmex Bets on Best of Breed

Sysmex Corp. of America and Roche Diagnostics are ending their four-year-old hematology alliance a year early. Both companies say the alliance has been successful. But Roche wants to focus on its franchises in fast-growing segments of the laboratory, and Sysmex, with a series of hematology product introductions underway, wants to raise its profile in the US. The move also signals an about-face from the initial premise for doing the deal, one which was widely pervasive throughout the medical device and diagnostics sectors in the 1990s: that customers want one-stop shopping and the discounts that come from bundling one manufacturer's broad product lines. Sysmex instead is turning to a best-of-breed strategy, which has served it well in major European markets, and which, it believes, will ultimately be more lucrative.

The winding down of the distribution and sales agreement between Sysmex Corp. of America and Roche Diagnostics in hematology a year early signals the start of a more aggressive US strategy for a strengthened Sysmex. In addition, it is indicative of the continuing dogged appeal of a best-of-breed strategy in a diagnostics market that extolled for much of the 1990s the alternative values of bundling and breadth of product line.

The announcement came in May in the form of an asset purchase agreement, in which Roche Diagnostics , a subsidiary...

More from Archive

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.